MAUDE Adverse Event Report: OLYMPUS AMERICA, INC EVIS EXERA II ULTRASOUND GASTROVIDEOSCOPE

Model Number TGF-UC180J

Device Problem Insufficient Information (3190)

Patient Problem Insufficient Information (4580)

Event Date 03/12/2022

Event Type  Injury  

Event Description

Olympus medical systems corp.(omsc) received a literature titled, "endoscopic ultrasound-guided porto-systemic pressure gradient measurement correlates with histological hepatic fibrosis." background and aims: endoscopic ultrasound is a novel diagnostic approach to chronic liver diseases (clds), and eus-guided porto-systemic pressure gradient measurement (eus-ppg) is an important expansion with a well-developed technique.However, the clinical value and applicability of eus-ppg measurement in predicting histologically advanced hepatic fibrosis remain unknown.Methods: this was a single-center retrospective study on patients with various clds undergoing eus-ppg and eus-guided liver biopsy (eus-bx) to assess if eus-ppg measurements correlate with histological fibrosis stage and various surrogate markers for severity of clds and its safety.Cases with eus-ppg were identified at (b)(6), a tertiary endoscopy center, between january 2014 and march 2020.Results in 64 patients, the mean age was 57.5; 40 (62.5%), males; mean child-turcotte-pugh (ctp) and model for end-stage liver disease (meld) scores, 5.9 and 10.4, respectively.The procedure success rate was 100%.Twenty-nine (45.3%) had eus-ppg=5 mmhg that was associated with clinical cirrhosis (p<0.0001), clinical portal hypertension (p=0.002), hepatic decompensation (p=0.013), meld-na>10 (p=0.036), plts=120×109/l (p=0.001), inr=1.05 (p=0.007), presence of ev, gv, or phg (p<0.0001), biopsy-proven fibrosis stage=3 (p=0.002), apri>2 (p=0.001), and fib-4>3.25 (p=0.001).Multivariable analysis confirmed that eus-ppg=5 mmhg was significantly associated with liver biopsy-proven fibrosis stage=3 (lr 27.0, 95% ci=1.653¿360.597, p=0.004), independent of c-cirrhosis, c-phtn, thrombocytopenia, splenomegaly, and apri score>2, and fib-4 score>3.25.There were no serious complications related to eus-ppg procedures.Conclusions: eus-ppg measurements provide excellent correlation with histological hepatic fibrosis stage and various clinical, laboratory, endoscopic and imaging variables indicative of advanced liver disease without serious adverse events.Type of adverse events/number of patients: cirrhosis thrombocytopenia.This literature article requires 3 reports.The related patient identifiers are as follows: (b)(6).This medwatch report is for patient identifier (b)(6).There is no report of any olympus device malfunction in any procedure described in this study.

• Brand Name: EVIS EXERA II ULTRASOUND GASTROVIDEOSCOPE
• Type of Device: ULTRASOUND GASTROVIDEOSCOPE
• Manufacturer (Section D): OLYMPUS AMERICA, INC; 3500 corporate parkway; center valley PA 18034 0610
• MDR Report Key: 16212158
• MDR Text Key: 307778012
• Report Number: 2429304-2023-00011
• Device Sequence Number: 1
• Product Code: ODG
• UDI-Device Identifier: 04953170328480
• UDI-Public: 04953170328480
• Combination Product (y/n): N
• Reporter Country Code: US
• Number of Events Reported: 1
• Summary Report (Y/N): N
• Report Source: Manufacturer
• Reporter Occupation: Physician
• Type of Report: Initial
• Report Date: 12/20/2022,01/19/2023

1 Device was Involved in the Event

1 Patient was Involved in the Event

• Date FDA Received: 01/19/2023
• Is this an Adverse Event Report?: Yes
• Is this a Product Problem Report?: No
• Device Operator: Health Professional
• Device Model Number: TGF-UC180J
• Is the Reporter a Health Professional?: Yes
• Was the Report Sent to FDA?: Yes
• Distributor Facility Aware Date: 12/20/2022
• Event Location: Outpatient Diagnostic Facility
• Date Report to Manufacturer: 12/20/2022
• Is This a Reprocessed and Reused Single-Use Device?: No
• Patient Sequence Number: 1
• Patient Outcome(s): Other